{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:42:30Z","timestamp":1791412950246,"version":"4.3.3"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J cachexia sarcopenia muscle"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Palliative systemic treatment in patients with advanced or metastatic esophagogastric cancer may result in improved overall survival and quality of life but can also lead to considerable toxicity. In various cancer types, severe muscle mass depletion (sarcopenia) and poor muscle strength are associated with decreased survival and increased chemotherapy\u2010related toxicity. The aim of this study is to determine the impact of body composition on survival and chemotherapy toxicity in esophagogastric cancer patients treated with first\u2010line palliative chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 88 patients with advanced esophagogastric cancer treated with standard first\u2010line palliative systemic therapy consisting of capecitabine and oxaliplatin (CapOx) between January 2010 and February 2017 were included. Skeletal muscle index (SMI), reflecting muscle mass, and skeletal muscle density (SMD), associated with muscle strength, were measured using pre\u2010treatment of all patients and evaluation computed tomography scans after three treatment cycles of 65 patients and were used to determine sarcopenia and sarcopenic obesity (i.e. sarcopenia and body mass index &gt;25\u00a0kg\/m<jats:sup>2<\/jats:sup>). The associations between body composition (SMI, SMD, sarcopenia, and sarcopenic obesity) and survival and toxicity were assessed using univariable and multivariable Cox and logistic regression analyses, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 88 patients, 75% was male, and median age was 63 (interquartile range 56\u201369) years. The majority of patients had an adenocarcinoma (83%). Before start of treatment, 49% of the patients were sarcopenic, and 20% had sarcopenic obesity. Low SMD was observed in 50% of patients. During three cycles CapOx, SMI significantly decreased, with a median decrease of 4% (interquartile range \u22128.6\u2013\u22120.4). Median progression\u2010free and overall survival were 6.9 and 10.1\u00a0months. SMI, SMD, sarcopenia, and sarcopenic obesity (both pre\u2010treatment and after three cycles) were neither associated with progression\u2010free nor overall survival. Pre\u2010treatment SMD was independently associated with grade 3\u20134 toxicity (odds ratio 0.94; 95% confidence interval 0.89\u20131.00) and sarcopenic obesity with grade 2\u20134 neuropathy (odds ratio 3.82; 95% confidence interval 1.20\u201312.18).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Sarcopenia was not associated with survival or treatment\u2010related toxicity in advanced esophagogastric cancer patients treated with CapOx. Pre\u2010treatment sarcopenic obesity was independently associated with the occurrence of grade 2\u20134 neurotoxicity and skeletal muscle density with grade 3\u20134 toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcsm.12371","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T21:39:53Z","timestamp":1548193193000},"page":"199-206","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3516-6743","authenticated-orcid":false,"given":"Willemieke P.M.","family":"Dijksterhuis","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC University of Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Pruijt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC University of Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie O.","family":"van der Woude","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC University of Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Klaassen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC University of Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie A.","family":"Kurk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht University of Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn G.H.","family":"van Oijen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC University of Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke W.M.","family":"van Laarhoven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC University of Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.008"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004064.pub3"},{"key":"e_1_2_7_4_1","article-title":"Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer","volume":"2017","author":"Janmaat VT","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25064"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073149"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2013.09.020"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.816421"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.2722"},{"key":"e_1_2_7_10_1","first-page":"1","article-title":"A review of body composition and pharmacokinetics in oncology","volume":"2433","author":"Hopkins JJ","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2242"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.4475"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2015.32"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1139\/H08-075"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00744.2004"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-018-1327-4"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002398"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003164"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9893"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-015-3963-1"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000011"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2015.05.011"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1747-0080.12306"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"e_1_2_7_25_1","first-page":"829","article-title":"Common Terminology Criteria for Adverse Events (CTCAE)","volume":"53","author":"National Institute of Cancer","year":"2010","journal-title":"NIH Publication"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12158"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-012-1923-5"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143327"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2015.08.005"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12155"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.6043"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e3281a30594"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.2000.89.1.104"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/apha.12224"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-015-0653-2"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx810"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.2174\/18715206113139990322"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017698643"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70153-0"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12206"},{"key":"e_1_2_7_41_1","first-page":"1","article-title":"Contrast\u2010enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomography","author":"Vugt JLA","year":"2017","journal-title":"Clin Nutr"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/cpf.12422"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12261"}],"container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcsm.12371","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.12371","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcsm.12371","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.12371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T18:42:27Z","timestamp":1694371347000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcsm.12371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1002\/jcsm.12371"],"URL":"https:\/\/doi.org\/10.1002\/jcsm.12371","archive":["Portico"],"relation":{},"ISSN":["2190-5991","2190-6009"],"issn-type":[{"value":"2190-5991","type":"print"},{"value":"2190-6009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,21]]},"assertion":[{"value":"2018-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}